Collaboration toward the OEM commercialization of LuBEA
First written in FY2016. 5 of 8 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「By treating glycans as diagnostic markers and contributing to the early detection of disease, our group aims to bring BIST, which it has developed over many years, and its dedicated instrument, LuBEA, into practical use in society.」
The policy of bringing GlycoBIST and LuBEA into practical use in society, together with the acquisition and validation of clinical data for IgA nephropathy, remained in place. - FY2025AdvancedAnnual report
「On 1 July 2025, we began selling the glycan-profiling system LuBEA-Ⅷ. The system uses our strengths in automation technology and patented technology, and we will pursue the commercialization of glycan biomarkers for kidney diseases including IgA nephropathy.」
LuBEA progressed from the clinical-data acquisition and validation-testing stage to the launch of LuBEA-Ⅷ sales and the pursuit of commercializing glycan biomarkers for kidney diseases. - FY2024AdvancedAnnual report
「More recently, we developed GlycoBIST for diagnosing IgA nephropathy, one of the kidney diseases for which noninvasive testing is awaited, and are acquiring clinical data and conducting validation tests through collaboration with medical institutions and others.」
For measurement systems including LuBEA, GlycoBIST was developed, and the project progressed to the stage of acquiring clinical data and conducting validation tests with medical institutions and others for IgA nephropathy. - FY2020RestatedAnnual report
「Although the prototype had already been completed, during the fiscal year we pursued collaboration with a company that possesses immune-response measurement technology, a potential customer, with the aim of commercializing the product. Commercialization has not yet been decided, but we have defined specific measurement parameters and are conducting various tests.」
Even after completion of the LuBEA prototype, collaboration and testing with potential customers were continuing, and commercialization remained undecided. - FY2019RestatedAnnual report
「Although the prototype had already been completed, during the fiscal year we pursued collaboration with a company that possesses immune-response measurement technology, a potential customer, with the aim of commercializing the product. Commercialization has not yet been decided, but we have defined specific measurement parameters and are conducting various tests.」
Even after completion of the LuBEA prototype, collaboration and testing with potential customers were continuing, and commercialization remained undecided. - FY2018RestatedAnnual report
「Although the prototype had already been completed, during the fiscal year we pursued collaboration with a company that possesses immune-response measurement technology, a potential customer, with the aim of commercializing the product as an OEM product. Commercialization has not yet been decided, but we have defined specific measurement parameters and are conducting various tests.」
Even after completion of the LuBEA prototype, collaboration and testing with potential customers were continuing, and commercialization remained undecided. - FY2017RestatedAnnual report
「Although the prototype had already been completed, during the fiscal year we pursued collaboration with a company that possesses immune-response measurement technology, a potential customer, with the aim of commercializing the product as an OEM product. Commercialization has not yet been decided, but we have defined specific measurement parameters and are conducting various tests.」
Even after completion of the LuBEA prototype, collaboration and testing with potential customers were continuing, and commercialization remained undecided. - FY2016First statedAnnual report
「Although the prototype had already been completed, during the fiscal year we pursued collaboration with a company that possesses immune-response measurement technology, a potential customer, with the aim of commercializing the product as an OEM product. Commercialization has not yet been decided, but we have defined specific measurement parameters and are conducting various tests.」
The prototype of the LuBEA multiplex measurement system had been completed, and the system was at the collaboration and testing stage with potential customers.